316 related articles for article (PubMed ID: 35496500)
1. Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
Kofla G; Radecke C; Frentsch M; Walther W; Stintzing S; Riess H; Bullinger L; Na IK
Oncoimmunology; 2022; 11(1):2068109. PubMed ID: 35496500
[TBL] [Abstract][Full Text] [Related]
2. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
3. Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity.
Sethuraman SN; Singh MP; Patil G; Li S; Fiering S; Hoopes PJ; Guha C; Malayer J; Ranjan A
Theranostics; 2020; 10(8):3397-3412. PubMed ID: 32206098
[No Abstract] [Full Text] [Related]
4. The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death.
Duan XC; Peng LY; Yao X; Xu MQ; Li H; Zhang SQ; Li ZY; Wang JR; Feng ZH; Wang GX; Liao A; Chen Y; Zhang X
Drug Deliv; 2021 Dec; 28(1):800-813. PubMed ID: 33866918
[TBL] [Abstract][Full Text] [Related]
5. Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner.
Mao L; Zhou JJ; Xiao Y; Yang QC; Yang SC; Wang S; Wu ZZ; Xiong HG; Yu HJ; Sun ZJ
Br J Cancer; 2023 Jun; 128(11):2126-2139. PubMed ID: 36977825
[TBL] [Abstract][Full Text] [Related]
6. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
[TBL] [Abstract][Full Text] [Related]
8. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
9. 4-(N)-Docosahexaenoyl 2', 2'-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent.
Hufnagel S; Xu H; Colemam MF; Valdes SA; Liu KA; Hursting SD; Cui Z
Cancer Chemother Pharmacol; 2022 Jan; 89(1):59-69. PubMed ID: 34698902
[TBL] [Abstract][Full Text] [Related]
10. A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.
Cultrara C; Uhl C; Kirby K; Abed Elrazaq E; Zellander A; Andrews DW; Scott CB; Galluzzi L; Exley MA; Zilberberg J
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37550054
[TBL] [Abstract][Full Text] [Related]
11. Chromomycin A
Florêncio KGD; Edson EA; Fernandes KSDS; Luiz JPM; Pinto FDCL; Pessoa ODL; Cunha FQ; Machado-Neto JA; Wilke DV
Front Immunol; 2022; 13():941757. PubMed ID: 36439184
[TBL] [Abstract][Full Text] [Related]
12. Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy.
Qiu N; Liu Y; Liu Q; Chen Y; Shen L; Hu M; Zhou X; Shen Y; Gao J; Huang L
Biomaterials; 2021 Feb; 269():120604. PubMed ID: 33383300
[TBL] [Abstract][Full Text] [Related]
13. Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases.
Eek Mariampillai A; Hauge S; Kongsrud K; Syljuåsen RG
Front Immunol; 2023; 14():1138920. PubMed ID: 37346039
[TBL] [Abstract][Full Text] [Related]
14. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
15. Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade.
Li Q; Chen C; Kong J; Li L; Li J; Huang Y
Acta Pharm Sin B; 2022 May; 12(5):2533-2549. PubMed ID: 35646521
[TBL] [Abstract][Full Text] [Related]
16. Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer.
Petersen SH; Kua LF; Nakajima S; Yong WP; Kono K
Sci Rep; 2021 Jun; 11(1):12264. PubMed ID: 34112882
[TBL] [Abstract][Full Text] [Related]
17. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.
Garg AD; Elsen S; Krysko DV; Vandenabeele P; de Witte P; Agostinis P
Oncotarget; 2015 Sep; 6(29):26841-60. PubMed ID: 26314964
[TBL] [Abstract][Full Text] [Related]
18. Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
Zhang S; Huang Y; Pi S; Chen H; Ye F; Wu C; Li L; Ye Q; Lin Y; Su Z
J Nanobiotechnology; 2023 Oct; 21(1):360. PubMed ID: 37789342
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal photochemotherapy induces bona fide immunogenic cell death.
Tatsuno K; Yamazaki T; Hanlon D; Han P; Robinson E; Sobolev O; Yurter A; Rivera-Molina F; Arshad N; Edelson RL; Galluzzi L
Cell Death Dis; 2019 Aug; 10(8):578. PubMed ID: 31371700
[TBL] [Abstract][Full Text] [Related]
20. CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
Li Y; Zhang H; Li Q; Zou P; Huang X; Wu C; Tan L
Cancer Lett; 2020 Dec; 495():12-21. PubMed ID: 32941949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
